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Introduction 
While only a cursory understanding of the hypothalamic-
pituitary-gonadal (HPG) axis is needed in general 
urological practice, practitioners of male sexual and 
reproductive medicine must have a thorough and deep 
understanding of the HPG axis and how alterations in this 
system can affect the physiology and pathophysiology of 
both spermatogenesis and testosterone production. The 
goal of our review is to highlight what is known about the 
endocrine system’s role in spermatogenesis and to discuss 
how derangements in this system can impair fertility.
Overview of the hypothalamic pituitary gonadal 
(HPG) axis
The hypothalamic pituitary gonadal axis is comprised of 
the hypothalamus, the pituitary gland (both anterior and 
posterior portions) and the testes. The hypothalamus 
secretes gonadotrophin releasing hormone (GnRH) in 
a pulsatile fashion, which enters the hypophyseal portal 
system in order to reach the anterior pituitary gland. 
This stimulates the anterior pituitary gland to secrete 
two hormones vital for reproduction, follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH), as well 
as adrenocorticotropin, growth hormone, prolactin, 
and thyroid-stimulating hormone(TSH) whose roles 
in reproduction at normal physiologic levels are poorly 
understood (1). LH and FSH act on cells in the testes 
including Leydig, Sertoli and germ cells. Leydig cells are 
the testosterone producing cells in the testicle, while Sertoli 
cells produce inhibin B. Both hormones feedback onto the 
anterior pituitary and the hypothalamus. Testosterone, once 
released into the peripheral circulation may be converted 
to estradiol by the enzyme aromatase, which can have 
effects on fertility. While elegant in its simple design, 
derangements in any of these steps can have tremendous 
impact on male fertility. 
Hypothalamic physiology—GnRH signaling
The discovery of peptide hormone signals from the 
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hypothalamus to the anterior pituitary was a Nobel prize 
winning discovery made by Roger Guillemin and Andrew 
Schally (2). Among these hormones, GnRH plays the most 
critical role in both male and female reproduction. GnRH is 
a short peptide hormone secreted by neurons that originate 
in the nasal placode. GnRH is secreted by neuronal endings 
directly into the hypophyseal circulation and binds to 
GnRH receptors located on pituitary gonadotrope cells in 
the anterior pituitary (3). GnRH activity is low in childhood 
and pulsatile secretion begins at puberty. This pulsatile 
secretion is key to normal reproductive functioning as 
early studies in animals and humans have shown that the 
pulsatility of GnRH secretion is essential in maintaining 
FSH and LH secretion (4-6). In fact, it is differing pulses 
in GnRH that lead to gonadotrope expression of LH over 
FSH, or vice versa, with LH synthesis being induced by 
fast GnRH pulses (>1 pulse per hour) and FSH by slower 
pulse frequencies (<1 pulse per 2–3 hours) (7). It is this 
knowledge of GnRH pulsations necessary to maintain LH 
and FSH secretion that may pave the way for “sperm safe” 
therapeutic approaches to the treatment of testosterone 
deficiency syndrome.
FSH and LH 
The critical role of the LH and follicle stimulating 
hormones (FSH) in mainting spermatogenesis (LH/FSH) 
and testosterone production (LH) is best illustrated by the 
condition of hypogonadotropic hypogonadism (HH). While 
Kallman’s syndrome (KS) is the prototypical form of HH, 
there is a continuum of disease of pubertal arrest, and not 
all patients with pubertal arrest will have olfactory defects 
like in KS. Men with this class of conditions typically have 
a defect in GnRH signaling leading to deficits in FSH and 
LH. FSH and LH signaling is essential for spermatogenesis 
to occur and, as a result, these patients are azoospermic. 
It has been shown that treatment of these patients with 
either pulsatile GnRH delivered by a pump or exogenous 
gonadotropin therapy combining human chorionic 
gonadotropin (hCG) (an LH analog) and FSH can lead 
the return of sperm in the ejaculate (8). However, though 
there often is return of sperm to the ejaculate and natural 
pregnancy is possible, these FSH and LH deficient patients 
may require a prolonged period of therapy with an average 
time to first return of sperm to the ejaculate of 11.3 months 
and a time to maximum sperm concentration of 24.9 months. 
Additionally, many of these couples will need assisted 
reproductive techniques to achieve pregnancy (9,10). 
Finally, it has been shown that GnRH administered in a 
pulsatile manner can initiate and maintain spermatogenesis 
in patients with hypogonadotropic hypogonadism to a 
similar degree than FSH and LH supplementation (11). 
Whether patients with partial or total pubertal arrest 
respond better to GnRH based treatments is an area of 
interest, though it seems that those with later arrest in 
puberty seem to do better with hCG and FSH injections (9). 
Given patients with HH will require years of costly 
FSH/hCG or GnRH injections, there has been research to 
investigate if hCG injection alone is sufficient to maintain 
spermatogenesis. The evidence is limited, with one study 
that looked at men with idiopathic HH who had been treated 
with a combination of FSH and hCG until sperm was seen 
back in their ejaculate. The authors were able to demonstrate 
that after spermatogenesis was induced, hCG could maintain 
a degree of spermatogenesis in most patients without the 
need for further FSH supplementation (12). Thus, these 
experiments show that although FSH is not essential for 
maintenance of spermatogenesis, it does have a critical role 
in the establishment of spermatogenesis, and experiments 
in humans where FSH and LH is suppressed by exogenous 
testosterone reveal that optimal FSH levels are necessary 
to achieve quantitatively normal spermatogenesis (13). 
Along these lines hCG monotherapy alone has been 
found to be useful in other scenarios such as maintaining 
testicular size and spermatogenesis in men using exogenous 
testosterone (14) and improving outcomes of testicular 
sperm retrieval in men with Kleinfelters and other forms 
of non-obstructive azoospermia (15,16). The theoretical 
mechanism by how hCG/LH maintains spermatogenesis 
is described later in this review as it involves regulation of 
intra-testicular testosterone.
For the clinician using hCG and FSH to induce 
spermatogenesis, the clinical question is how to determine 
the optimal dose and timing based on normal physiology. 
One can start by looking back at studies that show that 
there is a linear relationship between GnRH secretion and 
resultant LH production (17). Unfortunately, some studies 
on LH and FSH pulsatility suggest great variation among 
subjects in terms of secretory dose and pulsatility when 
measured in short time intervals. In fact it is even debated 
whether there are FSH pulses (5,18-20). Small-scale studies 
on hCG (or recombinant LH) may imply that low dose 
hCG divided into several doses (300 IU over 5 days) may 
be more effective at producing an optimal testosterone 
to estradiol ratio compared to a single larger dose 
(1,500 IU ×1 dose) (21). In contrast, one study shows that 
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hCG induces a biphasic response in testosterone production 
resulting in a peak at 2–4 hours and a higher one at 48 to 
72 hours after one administration of hCG (22). This finding 
would indicate that every third or fourth day dosing would 
be ideal. Guidance on FSH dosing is even more elusive as 
the clinically useful outcome, spermatogenesis, is typically 
checked at 2.5 to 3 months intervals making it difficult to 
study multiple FSH doses and regimens. Therefore, the 
optimal dosing regimen for either hormone remains elusive 
and is likely patient specific.
Testosterone
The LH produced by the pituitary gland eventually reaches 
the testicle inducing the production of testosterone from 
Leydig cells by stimulating the conversion of cholesterol 
into testosterone (23). Testosterone deficiency syndrome 
(TDS) can be characterized by a serologic laboratory value, 
generally total testosterone, below a certain pre-defined 
cutoff and symptoms such as decrease or loss of muscle 
strength, libido, memory, vitality, alterations in mood, and 
erectile dysfunction (ED) (24). Although this condition is 
typically considered exclusively in older men, symptoms 
of TDS, along with ED, are prevalent in patients being 
treated for male factor infertility, affecting up to one third 
of these patients (25,26). However, although there is a 
strong association between certain symptoms of TDS such 
as libido/sexual function with serologic markers such as 
total testosterone (27), this association has not been found 
to correlate with the TDS symptoms found in patients 
being treated for infertility (28). In fact, it is surmised that 
most of the sexual dysfunction symptoms typical of TDS in 
this population are of a psychogenic component (29). The 
role of testosterone’s contribution in ED found in infertile 
men is also controversial because it is not clear how much 
testosterone contributes to ED in older men, particularly 
those with co-morbid conditions (30). Despite the weak 
association of testosterone with sexual dysfunction in 
infertile men, testosterone remains an essential laboratory 
in the workup of an infertile patient given its role in 
spermatogenesis. 
The vital role of testosterone in human spermatogenesis 
is partially elucidated by previously cited studies where it 
has been shown that spermatogenesis could be stimulated 
with the LH analog hCG in patients who had active 
spermatogenesis prior to pituitary suppression (13,31). More 
intimate knowledge of the intra-testicular hormonal milieu 
was deciphered through the development of a percutaneous 
approach to test intra-testicular hormones in humans (32). 
These studies led to the finding that intra-testicular 
testosterone was roughly ten times higher than circulating 
testosterone and that its inhibition was associated with 
significant declines in spermatogenesis. These findings 
led to the concept that preservation of intra-testicular 
testosterone is necessary for spermatogenesis and clinically 
translates into a potential cutoff in circulating testosterone 
below which deficits in intra-testicular testosterone (ITT) 
are suspected. It is apparent that intratesticular testosterone 
levels similar to normal circulating serum testosterone 
concentrations are insufficient to support normal 
spermatogenesis, but besides that observation, no studies 
in humans exists that defines a cutoff of intratesticular 
or serum testosterone that is necessary to maintain 
spermatogenesis adequate enough to maintain normal male 
fertility potential (32). 
The above mentioned gap in knowledge of what a 
“normal” testosterone is in patients being evaluated for 
infertility leads one to rely on more current studies on 
testosterone levels in young men. One recent study helped 
define testosterone ranges in young men by measuring 
sample testosterone levels obtained during the conduction 
of several large cohort studies in a central Centers for 
Disease Control and Prevention (CDC) lab (33). This 
study revealed that 303 ng/dL was the fifth percentile 
value among healthy non-obese patients between 19 and 
39 years of age. Unfortunately without any access to semen 
analyses or other hormonal laboratories it is difficult to 
assess whether those in the fifth percentile or below had 
poorer semen quality. However, given these findings, it 
may not be unreasonable to treat certain patients with 
testosterone values less than 300 ng/dL and poor semen 
quality with agents that can increase ITT (34) Treatment 
strategies that may help increase ITT include the use of 
hCG injections or selective estrogen receptor modulators 
that block normal estrogen negative feedback leading to 
increase in endogenous FSH and LH (e.g., clomiphene 
citrate). It should be emphasized that trying to increase 
serum testosterone with exogenous testosterone will not 
help in this regard as it will decrease ITT by suppressing 
endogenous LH (as well as FSH) production due to 
negative feedback action on the hypothalamus and anterior 
pituitary. In fact, exogenous testosterone typically leads to a 
decline in spermatogenesis to the level of azoospermia in a 
majority of patients (35). 
S370
  Transl Androl Urol 2018;7(Suppl 3):S367-S372tau.amegroups.com© Translational Andrology and Urology. All rights reserved.
Clavijo and Hsiao. Update on male reproductive endocrinology
Estradiol 
As testosterone is produced and released into the 
bloodstream it reaches peripheral tissues, particularly fat, 
where it undergoes metabolism into estradiol by the enzyme 
aromatase (36). 
In a revelatory study by Finkelstein, it was shown that 
estradiol plays a fundamental role in body fat regulation 
as well as maintaining sexual desire (37). These findings 
are supported by observational studies correlating higher 
estradiol levels with improvement in libido in patients 
undergoing testosterone replacement (38). Studies on 
patients with aromatase deficiency begins to shed light 
on its role in fertility, particularly spermatogenesis. Case 
reports of this rare condition often reveal infertility due 
to oligospermia (39). The mechanism by which estradiol 
impacts spermatogenesis is likely related to its role, 
along with testosterone, in inhibiting LH production 
in the hypothalamus and pituitary (40). Thus it may be 
hypothesized that dysregulation of circulating estradiol 
may lead to altered LH pulse frequencies not ideal for 
spermatogenesis. The clinical utility of modifying estradiol 
is highlighted by the use of aromatase inhibitors in 
men with impaired semen parameters and an abnormal 
testosterone to estradiol ratio of (<10). Several groups 
have reported improvement in semen parameters after 
modifying this abnormal ratio suggesting high levels, or 
at least abnormal ratios, of estradiol are deleterious for 
spermatogenesis (41,42). The role of estradiol in testicular 
maturation as well as its impact on the local autocrine and 
paracrine hormonal milieu has also been studied, but its 
importance is not  completely defined at this level (43). 
Inhibins 
While LH is regulated mostly by estradiol and testosterone, 
FSH negative feedback occurs through inhibin hormones, 
particularly inhibin B which is produced in Sertoli cells (44). 
Although inhibins are produced independent of FSH, it 
has been shown that the quantity of inhibins is modulated 
tightly by FSH secretion supporting their inhibitory/
stimulatory relationship (45). It has been postulated that 
inhibin B may be a better marker of Sertoli cell mass, and 
therefore spermatogenesis, in patients not suffering from the 
histopathologic finding of maturation arrest. This is based 
on studies correlating inhibin B and sperm production as 
well as those showing lower inhibin B levels in patients with 
cryptorchidism with abnormal testicular histopathology and 
patients with varicoceles (46,47). However, unfamiliarity with 
clinical relevant ranges of inhibin B, the cost of obtaining the 
laboratory, and the lack of evidence showing its superiority 
to obtaining a serum FSH has potentially limited its clinical 
utility.
Conclusions
A properly  funct ioning HPG axis  i s  essent ia l  to 
spermatogenesis. Practitioners of male sexual and 
reproductive medicine must have an intimate and clear 
knowledge of this system and the effects of commonly 
used medications on the system in order to safely treat 
patients with impaired fertility. Partial or incomplete 
understanding of the system can easily lead to mistreatment 
and unexpected effects on spermatogenesis and libido. We 
have reviewed the basic physiology of the HPG axis, which 
is the foundation on which all hormonal manipulation in 
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